NTB-928 / 92Bio - LARVOL DELTA

Study of NTB-928 in R/R OC (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: TeneoSeven, Inc.

New P1 trial • Platinum resistant • Platinum sensitive • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor

92Bio, Inc. announced…the dosing of the first patient in a phase 1 clinical trial of NTB-928, a fully human bispecific T-cell engaging antibody (TCE) targeting folate receptor alpha (FOLR1) and CD3, in patients with platinum-resistant ovarian cancer (PROC). (BioPharm International) - "The first patient was dosed at START New York-Long Island in collaboration with Northwell Health Cancer Institute, under the direction of principal investigator Geraldine O'Sullivan Coyne, MD."

Platinum resistant • Trial status • Ovarian Cancer